First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well u...
Saved in:
| Main Authors: | E. Amabile, F. Fazio, M. Martelli, MT. Petrucci |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum to “First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report” [Leukemia Research Reports (2024) Volume 22, 100491]
by: E. Amabile, et al.
Published: (2025-01-01) -
Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature
by: Shuang Yu, et al.
Published: (2025-06-01) -
Delayed diagnosis of POEMS syndrome, how AI tools can enhance diagnostic accuracy
by: Max Jin, et al.
Published: (2025-06-01) -
VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.
by: Luca Laurenti, et al.
Published: (2022-01-01) -
POEMS SYNDROME: AN UPDATE
by: Andrea Nozza
Published: (2017-09-01)